{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"69.6","value":"44.9"},{"groupId":"OG001","spread":"62.9","value":"33.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Bendamustine"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Rituximab"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with FL received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6.","id":"OG000","title":"Arm B (Phase II Randomization): BR in FL"},{"description":"Participants with DLBCL received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6.","id":"OG001","title":"Arm D (Phase II Randomization): BR in DLBCL"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK evaluable population included all the ITT participants in Arms B and D who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema Vss was not evaluated for rituximab.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)","title":"Phase II: Vss of Bendamustine and Rituximab in Arms B and D","type":"SECONDARY","unitOfMeasure":"L"}